Abstract
The original observation that treatment of adult male rats with LHRH agonists causes a marked inhibition of testosterone secretion accompanied by a loss in secondary sex organ weight (Labrie et ai, 1978, 1980) opened a new era in the treatment of androgen-dependent diseases. When administered to adult men in appropriate doses by the subcutaneous route, these peptides decrease serum testosterone and dihydrotestosterone to castrated levels (Labrie et al., 1980; Faure et ai, 1982; Jacobi and Wenderoth, 1982). Since LHRH agonists have no adverse side effects other than those related to low circulating levels of androgens, they offer an advantageous alternative to orchiectomy and treatment with estrogens in advanced carcinoma of the prostate.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Armitage, T., 1971, Statistical Methods in Medical Research, Blackwell Scientific, Oxford.
Bartsch, W., Knabbe, B., and Voigt, K. D., 1983, Regulation and compartmentalization of androgens in rat prostate and muscle, J. Steroid Biochem. 19:929–937.
Faure, N., Labrie, F., Lemay, A., Bélanger, A., Gourdeau, Y., Laroche, B., and Robert, G., 1982, Inhibition of serum androgen levels by chronic intranasal administration of a potent LHRH agonist in adult men, Fertil. Steril. 37:416–424.
Geller, J., Albert, J. D., Nachtsheim, D. A., and Loza, D. C., 1984, Comparison of prostatic cancer tissue dehydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy, J. Urol. 132:693–696.
Goldman, A. J., and Elwood, J. M., 1979, Examining survival data, CMA J. 121:1065–1071.
Harper, M. E., Pike, A., Peeling, W. B., and Griffiths, K., 1974, Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro, J. Endocrinol. 60:117–125.
Huggins, C., and Scott, W. W., 1945, Bilateral adrenalectomy in prostatic cancer, Ann. Surg. 122:1031–1041.
Jacobi, G. H., and Wenderoth, U. K., 1982, Gonadotropin-releasing hormone analogs for prostatic cancer: Untoward side-effects of high dose regimens acquire a therapeutical dimension, Eur. Urol. 8:129–134.
Jordan, W. P., Jr., Blackard, C. E., and Byar, D. P., 1977, Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma, South. Med. J. 70:1411–1413.
Kahan, A., Delrieu, F., Amor, B., Chiche, R., and Steg, A., 1984, Disease flare induced by D-Trp6-LHRH analogue in patients with metastatic prostatic cancer, Lancet 1:971–972.
Kaplan, E. L., and Meier, P., 1958, Nonparametric estimation from incomplete observations, Am. Statist. Assoc. J. 53:457–481.
King, R. J. B., Cambray, G. J., Jagus-Smith, R., Robinson, J. H., and Smith, J. A., 1977, Steroid hormone and the control of tumor growth: Studies on androgen-responsive tumor cells in culture, in: Receptors and Mechanism of Action of Steroid Hormones (J. R. Pasqualini, ed.), Marcel Dekker, New York, pp. 215–227.
Labrie, F., Auclair, C., Cusan, L., Kelly, P. A., Pelletier, G., and Ferland, L., 1978, Inhibitory effects of LHRH and its agonists on testicular gonadotrophin receptors and spermatogenesis in the rat, Int. J. Androl. [Suppl.]2:303–318.
Labrie, F., Bélanger, A., Cusan, L., Séguin, C., Pelletier, G., Kelly, P. A., Lefebvre, F. A., Lemay, A., and Raynaud, J. P., 1980, Antifertility effects of LHRH agonists in the male, J. Androl. 1:209–228.
Labrie, F., Dupont, A., Bélanger, A., Cusan, L., Lacoursière, Y., Monfette, G., Laberge, J. G., Emond, J. P., Fazekas, A. T. A., Raynaud, J. P., and Husson, J. M., 1982, New hormonal therapy in prostatic carcinoma: Combined treatment with an LHRH agonist and an antiandrogen, Clin. Invest. Med. 5:267–275.
Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Raynaud, J. P., Husson, J M., Gareau, J., Fazekas, A. T. A., Sandow, J., Monfette, G., Girard, J. G., Emond, J. P., and Houle, J. G., 1983a, New approach in the treatment of prostate cancer: Complete instead of only partial withdrawal of androgens, Prostate 4:579–594.
Labrie, F., Dupont, A., Bélanger, A., Lefebvre, F. A., Cusan, L., Monfette, G., Laberge, J. G., Emond, J P., Raynaud, J. P., Husson, J. M., and Fazekas, A. T. A., 1983b, New hormonal treatment in cancer of the prostate: Combined administration of an LHRH agonist and an antian-drogen, J. Steroid Biochem. 19:999–1008.
Labrie, F., Bélanger, A., Dupont, A., Emond, J., Lacourcière, Y., and Monfette, G., 1984, Combined treatment with an LHRH agonist and a pure antiandrogen in advanced carcinoma of the prostate, Lancet 1:1090.
Labrie, F., Dupont, A., and Bélanger, A., 1985, Complete androgen blockade for the treatment of prostate cancer, in: Important Advances in Oncology (V. T. De Vita, Jr., S. Hellman, and S. A. Rosenberg, eds.), J. B. Lippincott, Philadelphia, pp. 193–217.
Leuprolide Study Group, 1984, Leuprolide versus diethylstilbestrol for metastatic prostate cancer, N. Engl. J. Med. 311:1281–1286.
Luthy, I., and Veilleux, R., 1985, The antiandrogen Flutamide® prevents the loss of androgen responsiveness in SC-115 mouse mammary carcinoma cells, in: Proceedings 67th Annual Meeting Endocrine Society, p. 193.
Mettlin, C., Natarajan, N., and Murphy, G. P., 1982, Recent patterns of care of prostatic cancer patients in the United States: Results from the surveys of the American College of Surgeons Commission on Cancer, Int. Adv. Surg. Oncol. 5:277–321.
Murphy, G. P., Beckley, S., Brady, M. F., Chu, M., DeKernion, J. B., Dhabuwala, C., Gaeta, J. F., Gibbons, R. P., Loening, S., McKiel, C. F., McLeod, D. G., Pontes, J. E., Prout, G. R., Scardino, P. T., Schlegel, J. U., Schmidt, J. D., Scott, W. W., Slack, N. H., and Soloway, M., 1983, Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone, Cancer 51:1264–1272.
Nesbit, R. M., and Baum, W. C., 1950, Endocrine control of prostatic carcinoma: Clinical and statistical survey of 1818 cases, J.A.M.A. 143:1317–1320.
Robinson, M. R. G., Shearer, R. J., and Fergusson, J. D., 1974, Adrenal suppression in the treatment of carcinoma of the prostate, Br. J. Urol. 46:555–559.
Simard, J., and Labrie, F., 1984, Unoccupied androgen receptors are biologically active in rat pituitary gonadotrophs. Excerpta Medica Congr. Ser. 652:9
Slack, N. H., Murphy, G. D., and NPCP participants, 1984, Criteria for evaluating patient responses to treatment modalities for prostatic cancer, Urol Clin. North Am. 11:337–342.
Sogani, P. C., Ray, B., and Whitmore, W. F. Jr., 1975, Advanced prostatic carcinoma: Flutamide® therapy after conventional endocrine treatment, Urology 6:164–166.
St.-Arnaud, R., Lachance, R., Kelly, S. J., Bélanger, A., Dupont, A., and Labrie, F., 1986, Loss of luteinizing hormone (LH) bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen, Clin. Endocrinol. 24:21–30.
Stoliar, B., and Albert, D. J., 1974, SCH 13521 in the treatment of advanced carcinoma of the prostate, J. Urol. 111:803–807.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Press, New York
About this chapter
Cite this chapter
Labrie, F. et al. (1986). Combined Treatment with an LHRH Agonist and the Antiandrogen Flutamide in Prostate Cancer. In: Moody, T.W. (eds) Neural and Endocrine Peptides and Receptors. GWUMC Department of Biochemistry Annual Spring Symposia. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5152-8_44
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5152-8_44
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5154-2
Online ISBN: 978-1-4684-5152-8
eBook Packages: Springer Book Archive